IL17A and colorectal cancer: In addition to the risk factors of progression reported by Caulet et al. [7] and regarding this cohort of patients with advanced colorectal cancer treated with a bevacizumab-based regimen, serum IL-17A baseline concentrations were identified as an independent factor and no influence of other Th17/Il-17A-related markers was observed.